Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 6/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | ACACA | Q13085 | 1/20 | 0.40 |
| ▸ | ITGB2 | P05107 | 3/20 | 0.40 |
| ▸ | ICAM1 | P05362 | 3/20 | 0.40 |
| ▸ | ITGAL | P20701 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12370119 | 0.91 | PIK3CA (0.44) | PIK3CAMAPK14MAOBACACBACACA | |
| SCHEMBL13167800 | 0.87 | PIK3CA (0.47) | PIK3CAMAPK14MAOBHDAC6ACACB | |
| SCHEMBL18885627 | 0.85 | HDAC6 (0.46) | PIK3CAMAPK14MAOBHDAC6ITGB2 | |
| SCHEMBL10156372 | 0.83 | PIK3CA (0.47) | PIK3CAMAPK14MAOBHDAC6ACACB | |
| SCHEMBL15498050 | 0.83 | HDAC6 (0.52) | PIK3CAMAOBHDAC6ITGB2ICAM1 | |
| SCHEMBL13821871 | 0.80 | ITGB2 (0.50) | HDAC6ITGB2ICAM1ITGAL | |
| SCHEMBL18867799 | 0.79 | ITGB2 (0.55) | ITGB2ICAM1ITGAL | |
| SCHEMBL12060482 | 0.78 | ITGB2 (0.49) | ITGB2ICAM1ITGAL | |
| SCHEMBL23176589 | 0.78 | HDAC6 (0.42) | HDAC6ITGB2ICAM1ITGAL | |
| SCHEMBL10157546 | 0.77 | ITGB2 (0.49) | ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124625-A1 | Modulators of Cellular Adhesion | SARCODE CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
| US-7745460-B2 | Modulators of cellular adhesion | SARCODE CORPORATION (US) | 2010-06-29 | — | — | US | disclosed |
| US-20080176896-A1 | Modulators of cellular adhesion | BAUSCH + LOMB IRELAND LIMITED (IE) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176896-A1 | Modulators of cellular adhesion | ITGB1, VCAM1, ITGB8 | PIK3CA 4193/4885MAPK14 4200/4885MAOB 1493/4885 |
| US-20110124625-A1 | Modulators of Cellular Adhesion | ITGB1, VCAM1, ITGB8 | PIK3CA 4193/4885MAPK14 4200/4885MAOB 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.